Dr Alberto Calvi, MD – neurologist, PhD has a decade of experience specializing in multiple sclerosis (MS) and neurodegenerative diseases. His work focuses on translating clinically relevant markers to support research into innovative treatments aimed at reducing disability progression.
During his neurology residency at the University of Milan, Italy, he contributed to research on genetic markers in neurodegenerative diseases, particularly exploring non-coding RNAs for clinical phenotype discrimination and prognostic applications. Following residency, he joined the Queen Square MS Centre at University College London (UCL), while he advanced MRI markers in progressive MS clinical trials and engaged in clinical neurology at the National Hospital for Neurology and Neurosurgery and the Royal London Hospital Trust. Over the years, Dr. Calvi successfully secured competitive fellowships (MAGNIMS, Guarantors of Brain, and UK MS Society) to support his PhD research at UCL, defended in November 2022. His subsequent ECTRIMS postdoctoral fellowship took him to Fundació Clinic por a la Recerca Biomedica (IDIBAPS), Spain, to continue his work on advanced imaging markers with the support of the European Committee on Treatment and Research in MS. His research includes pioneering work on chronic active lesions in MS, notably the development and application of slowly expanding lesions (SELs) as markers in clinical trials and observational studies. His publications in leading journals such as Neurology, Multiple Sclerosis Journal, and NeuroImage: Clinical reflect his contributions to the field. He has also developed expertise in neuroimaging analysis, neurological assessments, programming, and statistical methods using platforms like STATA and R.
Dr. Calvi is now senior advanced researcher at Hospital Clinic Barcelona (Spain), where he was awarded the Juan Rodes – Josep Baselga BBVA fellowship entitled: “Advanced magnetic resonance imaging (MRI) and artificial intelligence (AI)-based prognosis in latent multiple sclerosis: development of a comprehensive methodology to assess progression.” Since 2023, Dr. Calvi has started an active collaboration with the Judith Jaffe Multiple Sclerosis Center, Weill Cornell Medicine (WCM) New York (USA), a world-leading center for MS imaging research. The two centres share the main goal of identifying markers that can improve the assessment of tissue damage in MS to transfer them to clinical practice.
